Literature DB >> 20539824

Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?

Stephen A Varvel1, Laura E Wise, Aron H Lichtman.   

Abstract

For more than a decade, a considerable amount of research has examined the effects of rimonabant (SR 141716) and other CB(1) receptor antagonists in both in vivo and in vitro models of learning and memory. In addition to its utility in determining whether the effects of drugs are mediated though a CB(1) receptor mechanism of action, these antagonists are useful in providing insight into the physiological function of the endogenous cannabinoid system. Several groups have reported that CB(1) receptor antagonists enhance memory duration in a variety of spatial and operant paradigms, but not in all paradigms. Conversely, disruption of CB(1) receptor signaling also impairs extinction learning in which the animal actively suppresses a learned response when reinforcement has been withheld. These extinction deficits occur in aversively motivated tasks, such as in fear conditioning or escape behavior in the Morris water maze task, but not in appetitively motivated tasks. Similarly, in electrophysiological models, CB(1) receptor antagonists elicit a variety of effects, including enhancement of long-term potentiation (LTP), while disrupting long-term depression (LTD) and interfering with transient forms of plasticity, including depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). The collective results of the in vivo and in vitro studies employing CB(1) receptor antagonists, demonstrate that these receptors play integral roles in different components of cognitive processing. Functionally, pharmacological blockade of CB(1) receptors may strengthen memory duration, but interferes with extinction of learned behaviors that are associated with traumatic or aversive memories.

Entities:  

Year:  2009        PMID: 20539824      PMCID: PMC2882689          DOI: 10.1002/ddr.20334

Source DB:  PubMed          Journal:  Drug Dev Res        ISSN: 0272-4391            Impact factor:   4.360


  101 in total

1.  6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

Authors:  Adèle Thomas; Ruth A Ross; Bijali Saha; Anu Mahadevan; Raj K Razdan; Roger G Pertwee
Journal:  Eur J Pharmacol       Date:  2004-03-08       Impact factor: 4.432

2.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

3.  Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes.

Authors:  Kornelia Kamprath; Giovanni Marsicano; Jianrong Tang; Krisztina Monory; Tiziana Bisogno; Vincenzo Di Marzo; Beat Lutz; Carsten T Wotjak
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

4.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

5.  Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

Authors:  N Auclair; S Otani; P Soubrie; F Crepel
Journal:  J Neurophysiol       Date:  2000-06       Impact factor: 2.714

6.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

7.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum.

Authors:  G L Gerdeman; J Ronesi; D M Lovinger
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

8.  Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells.

Authors:  T A Pitler; B E Alger
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

9.  CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice.

Authors:  Astrid Cannich; Carsten T Wotjak; Kornelia Kamprath; Heike Hermann; Beat Lutz; Giovanni Marsicano
Journal:  Learn Mem       Date:  2004 Sep-Oct       Impact factor: 2.460

10.  Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Authors:  R S Mansbach; C C Rovetti; E N Winston; J A Lowe
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

View more
  3 in total

1.  Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.

Authors:  Jenny Ceccarini; Cindy Casteels; Rawaha Ahmad; Melissa Crabbé; Laura Van de Vliet; Heleen Vanhaute; Mathieu Vandenbulcke; Wim Vandenberghe; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-24       Impact factor: 9.236

2.  Δ9-Tetrahydrocannabinol During Encoding Impairs Perceptual Details yet Spares Context Effects on Episodic Memory.

Authors:  Manoj K Doss; Jessica Weafer; David A Gallo; Harriet de Wit
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-08-30

3.  Effects of endocannabinoid system modulation on cognitive and emotional behavior.

Authors:  Claudio Zanettini; Leigh V Panlilio; Mano Alicki; Steven R Goldberg; József Haller; Sevil Yasar
Journal:  Front Behav Neurosci       Date:  2011-09-13       Impact factor: 3.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.